However, the AT1R antagonist Valsartan can inhibit CK2 activation post-MI, eliminate CK2 phosphorylation of Sp1, increase Kir2.1 expression, and improve IK1 remodeling, suggesting a new treatment strategy for post-MI arrhythmia. The gene discussed is KCNJ2; the disease is myocardial infarction.